Company Filing History:
Years Active: 2003-2008
Title: Uwe Kollenkirchen: Innovator in Selective Estrogens
Introduction
Uwe Kollenkirchen is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective estrogens. With a total of four patents to his name, Kollenkirchen's work focuses on innovative compounds that have therapeutic applications.
Latest Patents
Kollenkirchen's latest patents include the invention of 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens. This invention describes new 8β-substituted estratrienes that serve as pharmaceutical active ingredients. These compounds exhibit a higher affinity for estrogen receptor preparations of rat prostates compared to those of rat uteri. They are designed to preferentially act on bone rather than the uterus, making them valuable for treating estrogen-deficiency-induced diseases. Another significant patent involves 18-norsteroids as selectively active estrogens. These compounds also show a high affinity for estrogen receptors and are aimed at treating similar conditions.
Career Highlights
Kollenkirchen is associated with Schering Aktiengesellschaft, a prominent pharmaceutical company. His work has led to advancements in the understanding and treatment of estrogen-related conditions. His innovative approach to drug development has positioned him as a key figure in the pharmaceutical industry.
Collaborations
Throughout his career, Kollenkirchen has collaborated with notable colleagues such as Karl-Heinrich Fritzemeier and Christa Hegele-Hartung. These collaborations have further enhanced the research and development of his patented compounds.
Conclusion
Uwe Kollenkirchen's contributions to the field of selective estrogens highlight his innovative spirit and dedication to improving healthcare. His patents reflect a commitment to addressing critical medical needs through advanced pharmaceutical solutions.